Gilder Gagnon Howe & Co’s Madrigal Pharmaceuticals MDGL Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.4M	Sell	29,391 -4,077	-12%	-$1.95M	0.18%	95
2025 Q4	$19.5M	Buy	33,468 +2,620	+8%	+$1.34M	0.21%	91
2025 Q3	$14.1M	Sell	30,848 -705	-2%	-$263K	0.14%	105
2025 Q2	$9.55M	Sell	31,553 -103	-0.3%	-$30.7K	0.1%	115
2025 Q1	$10.5M	Sell	31,656 -4,512	-12%	-$1.48M	0.14%	103
2024 Q4	$11.2M	Sell	36,168 -1,965	-5%	-$553K	0.12%	115
2024 Q3	$8.09M	Sell	38,133 -244	-0.6%	-$62.4K	0.1%	120
2024 Q2	$10.8M	Sell	38,377 -706	-2%	-$168K	0.13%	112
2024 Q1	$10.4M	Buy	+39,083	New	+$9.21M	0.13%	115

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's MDGL Position: Q1 2026 in Review

Gilder Gagnon Howe & Co reduced its Madrigal Pharmaceuticals (MDGL) stake by 12% in Q1 2026, selling an estimated $1.95M and leaving 29,391 shares worth $15.4M. The position accounts for 0.18% of the portfolio, ranked #95.

Gilder Gagnon Howe & Co first reported a position in MDGL in Q1 2024 and has held it in 9 quarters since. The position peaked at $19.5M in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Gilder Gagnon Howe & Co held 29,391 shares of Madrigal Pharmaceuticals worth $15.4M as of Q1 2026.
Gilder Gagnon Howe & Co sold 4,077 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $1.95M.
Madrigal Pharmaceuticals made up 0.18% of Gilder Gagnon Howe & Co's portfolio in Q1 2026, its #95 holding.
Gilder Gagnon Howe & Co first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
Gilder Gagnon Howe & Co's Madrigal Pharmaceuticals position peaked at $19.5M in Q4 2025.
378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2026, filed 15 May 2026.